Shares of Applied Genetic Technologies Corp. (NASDAQ:AGTC) dropped 1.2% during trading on Monday . The company traded as low as $15.12 and last traded at $15.22, with a volume of 81,533 shares traded. The stock had previously closed at $15.40.

AGTC has been the subject of a number of research reports. Roth Capital reissued a “buy” rating on shares of Applied Genetic Technologies Corp. in a research note on Monday, April 25th. Wedbush reissued an “outperform” rating and set a $36.00 target price on shares of Applied Genetic Technologies Corp. in a research note on Tuesday, May 10th. Cantor Fitzgerald reissued a “buy” rating and set a $32.00 target price on shares of Applied Genetic Technologies Corp. in a research note on Tuesday, May 10th. Wells Fargo & Co. reissued a “buy” rating on shares of Applied Genetic Technologies Corp. in a research note on Tuesday, May 10th. Finally, Zacks Investment Research raised shares of Applied Genetic Technologies Corp. from a “hold” rating to a “buy” rating and set a $15.00 target price for the company in a research note on Wednesday, May 11th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $26.00.

The stock’s 50 day moving average is $15.22 and its 200 day moving average is $15.07. The firm’s market capitalization is $274.46 million.

A hedge fund recently raised its stake in Applied Genetic Technologies Corp. stock. Jennison Associates LLC boosted its stake in Applied Genetic Technologies Corp. (NASDAQ:AGTC) by 0.5% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 677,610 shares of the company’s stock after buying an additional 3,248 shares during the period. Jennison Associates LLC owned 3.76% of Applied Genetic Technologies Corp. worth $13,823,000 at the end of the most recent quarter.

Applied Genetic Technologies Corp is a United States-based clinical stage biotechnology company. The Company develops gene therapy products for the treatment of inherited and acquired diseases. Its products are used to treat Alpha One Antitrypsin Deficiency (Alpha-1), a respiratory disease caused by deficiencies in the tissue protective protein alpha one antitrypsin; and Lebers congenital amaurosis, an inherited condition causing early blindness.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.